QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics

QuidelOrtho Corporation has finalized its acquisition of LEX Diagnostics for approximately $100 million, a significant move aimed at enhancing its capabilities in the point-of-care molecular diagnostics sector. The deal, completed on April 20, 2026, allows QuidelOrtho to expand its product offerings with the innovative LEX VELO System, which is designed to deliver rapid PCR testing results within approximately six to ten minutes.

The LEX VELO System represents a breakthrough in molecular diagnostics, providing highly sensitive, multiplex RT-PCR testing for Influenza A, Influenza B, and COVID-19 directly from a swab sample. This system has recently received FDA 510(k) clearance and a CLIA waiver, positioning it as a pivotal tool for healthcare providers seeking to make timely clinical decisions in decentralized care environments. The acquisition aligns with QuidelOrtho's strategic goal to accelerate growth in the rapidly expanding diagnostics market, particularly in point-of-care settings.

QuidelOrtho, a leader in in vitro diagnostics, has a diverse portfolio that includes immunoassay, clinical chemistry, and transfusion medicine. The addition of the LEX VELO System complements its existing offerings and reinforces the company's position in the diagnostics landscape. By integrating this ultra-fast PCR platform into its operations, QuidelOrtho aims to enhance its ability to deliver comprehensive diagnostic solutions across various healthcare settings, from hospitals to clinics.

The anticipated U.S. commercial launch of the LEX VELO System later this year is expected to drive significant growth for QuidelOrtho. The company plans to expand its reach globally, contingent upon local regulatory approvals. This strategic acquisition not only enhances QuidelOrtho's product lineup but also reflects its commitment to advancing diagnostics that improve patient outcomes and streamline healthcare delivery.

In the broader context, this acquisition underscores the increasing demand for rapid and accurate diagnostic solutions in the healthcare sector. As the industry continues to evolve, companies that can effectively leverage innovative technologies like the LEX VELO System are likely to capture market share and drive growth. The transaction highlights the ongoing consolidation trends within the diagnostics market, as firms seek to bolster their capabilities and respond to the changing needs of healthcare providers and patients alike.